Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race

Executive Summary

The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.

Advertisement

Related Content

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas
Gene Therapy Investment At All Time High, Commercialization Challenges Noted
Bayer Bosses Beg Risk-Averse Europe To Rethink
Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza
Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies
Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy
Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity
Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign
The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel